Literature DB >> 29621648

Integrating phosphoproteomics into kinase-targeted cancer therapies in precision medicine.

Xiaomo Wu1, Xiaohua Xing2, Djameel Dowlut2, Yongyi Zeng2, Jingfeng Liu3, Xiaolong Liu4.   

Abstract

Protein phosphorylation is a post-translational modification that is involved in the regulation of all major biological processes in cells. As a rapid and reversible means to modulate protein activity and transduce signals, aberrant protein phosphorylation is implicated in the onset and progression of most cancer types. Therefore, pharmacological inhibitors against protein kinases are highly pursued therapeutic approaches for treating cancer. Phosphoproteomics has become an important approach for investigating protein phosphorylation, and it is a technique that provides measurements of kinase pathway activation and the circuitry of signalling networks with both spatial and temporal resolution. Combined with the recent advances in mass spectrometry and development in biochemical procedures for phosphopeptide enrichment and computational approaches, high-throughput phosphoproteomics enables the investigation of kinase signalling networks with unprecedented depth. Here, we review the recent progresses in phosphoproteomics methodology and how phosphoproteomics profiling could be implemented in translational research to aid cancer therapies, facilitate novel drug target discovery and overcome the therapeutic obstacles caused by drug resistance. SIGNIFICANCE: In this review, we summarized the recent progress in mass spectrometry-based phosphoproteomics and discussed how phosphoproteomics profiling can be implemented in translational research to aid cancer therapies, facilitate novel drug target discovery and overcome the therapeutic obstacles caused by drug resistance due to the rapid remodelling of signalling networks in response to kinase inhibitor treatment. In addition, we addressed the insights and challenges of applying MS phosphoproteomics in clinical routine practice in precision medicine. This review will help readers become more familiar with the recent advancements and applications of phosphoproteomics, especially in the field of kinase-targeted cancer therapy.
Copyright © 2018. Published by Elsevier B.V.

Entities:  

Keywords:  Drug resistance; Kinase inhibitors; Phosphoproteomics; Precision medicine

Mesh:

Substances:

Year:  2018        PMID: 29621648     DOI: 10.1016/j.jprot.2018.03.033

Source DB:  PubMed          Journal:  J Proteomics        ISSN: 1874-3919            Impact factor:   4.044


  10 in total

1.  Quantitative Phosphoproteomics Reveals Extensive Protein Phosphorylation Dysregulation in the Cerebral Cortex of Huntington's Disease Mice Prior to Onset of Symptoms.

Authors:  Isaline Mees; Harvey Tran; Anne Roberts; Larissa Lago; Shanshan Li; Blaine R Roberts; Anthony J Hannan; Thibault Renoir
Journal:  Mol Neurobiol       Date:  2022-01-27       Impact factor: 5.590

2.  Integrated proteogenomic characterization of urothelial carcinoma of the bladder.

Authors:  Ning Xu; Zhenmei Yao; Guoguo Shang; Dingwei Ye; Haixing Wang; Hailiang Zhang; Yuanyuan Qu; Jun Hou; Fujiang Xu; Yunzhi Wang; Zhaoyu Qin; Jiajun Zhu; Fan Zhang; Jinwen Feng; Sha Tian; Yang Liu; Jianyuan Zhao; Jianming Guo; Yingyong Hou; Chen Ding
Journal:  J Hematol Oncol       Date:  2022-06-03       Impact factor: 23.168

3.  RSK3 mediates necroptosis by regulating phosphorylation of RIP3 in rat retinal ganglion cells.

Authors:  Mi Wang; Hao Wan; Shuchao Wang; Lvshuang Liao; Yanxia Huang; Limin Guo; Fengxia Liu; Lei Shang; Jufang Huang; Dan Ji; Xiaobo Xia; Bin Jiang; Dan Chen; Kun Xiong
Journal:  J Anat       Date:  2020-03-12       Impact factor: 2.921

4.  Phosphoproteomics of short-term hedgehog signaling in human medulloblastoma cells.

Authors:  Tamara Scheidt; Oliver Alka; Humberto Gonczarowska-Jorge; Wolfgang Gruber; Florian Rathje; Margherita Dell'Aica; Marc Rurik; Oliver Kohlbacher; René P Zahedi; Fritz Aberger; Christian G Huber
Journal:  Cell Commun Signal       Date:  2020-06-23       Impact factor: 5.712

Review 5.  Therapeutic Targeting of mTOR in T-Cell Acute Lymphoblastic Leukemia: An Update.

Authors:  Camilla Evangelisti; Francesca Chiarini; James A McCubrey; Alberto M Martelli
Journal:  Int J Mol Sci       Date:  2018-06-26       Impact factor: 5.923

Review 6.  Targeting mTOR in Acute Lymphoblastic Leukemia.

Authors:  Carolina Simioni; Alberto M Martelli; Giorgio Zauli; Elisabetta Melloni; Luca M Neri
Journal:  Cells       Date:  2019-02-21       Impact factor: 6.600

Review 7.  Application of PD-1 Blockade in Cancer Immunotherapy.

Authors:  Xiaomo Wu; Zhongkai Gu; Yang Chen; Borui Chen; Wei Chen; Liqiang Weng; Xiaolong Liu
Journal:  Comput Struct Biotechnol J       Date:  2019-05-23       Impact factor: 7.271

Review 8.  Functions and therapeutic potential of protein phosphatase 1: Insights from mouse genetics.

Authors:  Mónica Ferreira; Monique Beullens; Mathieu Bollen; Aleyde Van Eynde
Journal:  Biochim Biophys Acta Mol Cell Res       Date:  2018-07-26       Impact factor: 4.739

Review 9.  Mass Spectrometric-Based Proteomics for Biomarker Discovery in Osteosarcoma: Current Status and Future Direction.

Authors:  Nutnicha Sirikaew; Dumnoensun Pruksakorn; Parunya Chaiyawat; Somchai Chutipongtanate
Journal:  Int J Mol Sci       Date:  2022-08-28       Impact factor: 6.208

10.  Phosphoproteomics Enables Molecular Subtyping and Nomination of Kinase Candidates for Individual Patients of Diffuse-Type Gastric Cancer.

Authors:  Mengsha Tong; Chunyu Yu; Jinwen Shi; Wenwen Huang; Sai Ge; Mingwei Liu; Lei Song; Dongdong Zhan; Xia Xia; Wanlin Liu; Jinwen Feng; Wenhao Shi; Jiafu Ji; Jing Gao; Tieliu Shi; Weimin Zhu; Chen Ding; Yi Wang; Fuchu He; Lin Shen; Tingting Li; Jun Qin
Journal:  iScience       Date:  2019-11-06
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.